FDA authorizes emergency use for Pfizer vaccine

Pfizer logo.
(Image credit: JEFF KOWALSKY/AFP via Getty Images)

The Food and Drug Administration on Friday night authorized the COVID-19 vaccine developed by Pfizer and BioNTech for emergency use, a potentially major step toward ending the coronavirus pandemic.

The still-experimental vaccine, which was found to be more than 90 percent effective in late-stage clinical trials and does not appear to cause severe side effects, is expected to be rolled out for health care workers and long-term care facility residents in the coming days, the first phase of what should be the largest vaccination campaign in U.S. history. Immediate distribution will be limited, with about 3 million doses expected in the initial shipments, but the goal is to vaccinate 20 million people by the end of the December, and another 30 million and 50 million in January and February, respectively. A second vaccine developed by Moderna, which could receive emergency use authorization as early as next week, would theoretically contribute to that total.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.